Tenapanor + Sevelamer Carbonate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, End Stage Renal Disease
Trial Timeline
Jun 15, 2019 → Jul 31, 2021
NCT ID
NCT03988920About Tenapanor + Sevelamer Carbonate
Tenapanor + Sevelamer Carbonate is a approved stage product being developed by Ardelyx for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03988920. Target conditions include Hyperphosphatemia, End Stage Renal Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03988920 | Approved | Completed |
Competing Products
20 competing products in Hyperphosphatemia